Drug Safety Board Is Biased By Connection To CDER, Sen. Grassley Says
This article was originally published in The Tan Sheet
Sen. Charles Grassley (R-Iowa) is asking FDA to outline what actions the agency will take to ensure that the Drug Safety Oversight Board is "objective.
You may also be interested in...
Department of Veterans Affairs pharmacy benefit management advisor Chester Good brings experience with drug-related adverse event reporting to FDA's Drug Safety Oversight Board
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning